DaVita faces securities fraud investigation after kidney care policy causes stock drop

Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to increase competition and shift incentives toward early preventive kidney care, which led to a 6.23% fall in DaVita's share price on October 20, 2026. The investigation will determine if DaVita and its executives engaged in unlawful business practices amid these regulatory changes.

DaVita Inc. shares continue to face selling pressure on Pluang, with 93% of order activity as sell and the stock down 1.13% at USD 181.95. The market cap stands at $11.74 billion, reflecting ongoing investor caution. These figures are as of October 28, 2026, 05:02 WIB.